23 Apr 2008
Patients with attention deficit hyperactivity disorder (ADHD) should receive cardiac evaluation prior to treatment with stimulant medication, experts state.
The statement by the American Heart Association (AHA) follows warnings from the US Food and Drug Administration concerning the safety of stimulant medications in recent years.
Studies have raised concerns over the potential cardiovascular effects of psychotropic drugs, particularly tricyclic antidepressants, as well as stimulants.
ADHD stimulants have been associated with increased heart rate and blood pressure alongside the risk of sudden cardiac death (SCD).
The AHA's statement recommends adding an electrocardiogram to pre-treatment evaluations for children with ADHD.
"After ADHD is diagnosed, but before therapy with a stimulant or other medication is begun, we suggest that an ECG be added to the pre-treatment evaluation to increase the likelihood of identifying cardiac conditions that may place the child at risk for sudden death," Victoria Vetter, head of the statement writing committee, said.
"While we feel that an ECG is reasonable and helpful as a tool to identify children with cardiac conditions that can lead to SCD, if, in the view of their physician, a child requires immediate treatment with stimulant medications, this recommendation is not meant to keep them from getting that treatment," Ms Vetter added.
Future studies are necessary to assess the true risk of SCD in association with stimulant drugs in children and adolescents with and without heart disease, she concluded.
Register now to access our FREE educational library
Print Article 
Bookmark
- Study dismisses sugar as encouraging hyperactivity 18/12/08
- ADHD symptoms may affect ability to quit smoking, study suggests 24/11/08
- ADHD drugs' genetic damage fears allayed in new study 21/11/08
- Movement study shows difference in sexes for ADHD sufferers 04/11/08
- ADHD and serious nicotine addiction risk 24/10/08
Disease Knowledge Centres feed
-
CONCERTA XL Prolonged-release Tablets - 49.42%
CONCERTA® XL is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children (over 6 years of age) and adolescents when remedial measures alone prove insufficient. Diagnosis must be made according to DSM-IV criteria or the guidelines in ICD ... -
EQUASYM Tablets - 47.03%
Methylphenidate is indicated as part of a comprehensive treatment programme for attention-deficit hyperactivity disorder (ADHD) in children over 6 years of agewhen remedial measures alone prove insufficient. The decision to treat as well as follow-up must be under supervision of a specialist in ... -
EQUASYM XL Capsules - 46.1%
Equasym XL is indicated as part of a comprehensive treatment programme for attention-deficit/hyperactivity disorder (ADHD) in children over 6 years of age when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders ... -
STRATTERA - 46.1%
Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older and in adolescents as part of a comprehensive treatment programme. Diagnosis should be made according to DSM-IV criteria or the guidelines in ICD-10. Additional information ... -
RITALIN - 46.1%
Indicated for the treatment of Attention-deficit Hyperactivity Disorder. (ADHD ... -
DEXEDRINE - 46.1%
Narcolepsy; refractory hyperkinetic states in children under specialist supervision. (ADHD ...
Printed on 10/01/2009 12:29 AM
